• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.net
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Tech

VASRO GmbH > Press > Tech
VASRO GmbH

TSMC Ergebnisse für das 3. Quartal 2025 und KI-Kapazität

  • October 17, 2025
  • Tech
TSMC’s Q3 2025 results show record profits and major AI capacity expansion, positioning the company as a leader in advanced AI chip manufacturing.
Continue Reading
VASRO GmbH

GDPR for health data and the establishment of a compliant real-world evidence pipeline in Germany

  • September 30, 2025
  • Tech
DSGVO für Gesundheitsdaten: So baust du eine konforme Real-World Evidence Pipeline in Deutschland auf und erfüllst alle Datenschutzanforderungen.
Continue Reading
VASRO GmbH

PPA-Preise für den Mittelstand: Wie deutsche Hersteller 5–10-jährige erneuerbare PPAs strukturieren

  • September 5, 2025
  • Tech
PPA-Preise für den Mittelstand: Erfahre, wie deutsche Hersteller 5–10-jährige erneuerbare PPAs strukturieren und welche Preisbereiche aktuell marktüblich sind.
Continue Reading
VASRO GmbH

Quality of German SaaS: NRR, payback, and net retention

  • September 3, 2025
  • Tech
Qualität von deutschen SaaS messen: NRR, Payback und Net Retention zeigen Wachstum, Kundenbindung und Effizienz. Benchmarks und Tipps für nachhaltigen Erfolg.
Continue Reading
VASRO GmbH

EU-KI-Gesetzesvorbereitung: Verpflichtungen für SaaS-Anbieter und Bereitsteller und was im 4. Quartal 2025 zu tun ist

  • September 1, 2025
  • Tech
EU AI-Gesetz Bereitschaft: Was SaaS-Anbieter und -Einsetzer bis Q4 2025 beachten und umsetzen müssen, um Compliance und Sicherheit zu gewährleisten.
Continue Reading
VASRO GmbH

Top 5 AI Stocks: Equity Report Analysis of Leading Tech Innovators

  • August 1, 2025
  • Tech
Top 5 KI-Aktien im Vergleich: Chancen, Risiken und Analysen führender Tech-Innovatoren für Anleger. Jetzt die wichtigsten Unterschiede und Trends erfahren.
Continue Reading
VASRO GmbH

Top Equity Report Tools: Software and Data Platforms for Investors in 2025

  • July 14, 2025
  • Tech
Top-Aktienbericht-Tools 2025: Die besten Software-Lösungen und Datenplattformen für Investoren mit Fokus auf Analyse, Datenqualität und Sicherheit.
Continue Reading
VASRO GmbH

Why Equity Research Matters in the Era of AI Layoffs

  • February 14, 2025
  • Pharma & Biotech, Pharma & Biotech, Tech, Tech
AI layoffs and market shifts demand equity research to guide investors and companies. Discover how it identifies risks, opportunities, and ensures resilience.
Continue Reading
VASRO GmbH

The Impact of AI on Drug Development Strategies in 2025

  • February 11, 2025
  • Pharma & Biotech, Pharma & Biotech, Tech, Tech
AI revolutionizes drug development in 2025, enhancing efficiency, reducing costs, and driving innovation in the Drug Development Pipeline Insights 2025.
Continue Reading
VASRO GmbH

How AI is Transforming Drug Discovery Processes in 2025

  • February 6, 2025
  • Pharma & Biotech, Pharma & Biotech, Tech, Tech
The impact of AI on drug discovery in 2025 is profound, reducing costs, accelerating timelines, and improving success rates in clinical trials and drug design.
Continue Reading

Posts pagination

1 2 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY September 7, 2026
Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY August 31, 2026
Spinneys 1961 Holding PLC: The Estate Grew 17%, Demand Did Not — First Half 2026 Update August 12, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • Info@vasro.net
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.